We are live on ! Find out more
GBIO

Generation Bio
GBIO

Delisted

GBIO was delisted on the 6th of February, 2026.

Back to rankings

88 hedge funds and large institutions have $390M invested in Generation Bio in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 14

26% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 23

21% more call options, than puts

Call options by funds: $110K | Put options by funds: $91K

9% more funds holding

Funds holding: 81 → 88 (+7)

1.21% more ownership

Funds ownership: 8.45% → 9.66% (+1.2%)

68% less capital invested

Capital invested by funds: $1.2B → $390M (-$813M)

Holders
88
Holders Change
+7
Holders Change %
+8.64%
% of All Funds
1.35%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
29
Reduced
23
Closed
14
Calls
$110K
Puts
$91K
Net Calls
+$19K
Net Calls Change
+$2.7M

Top Buyers

Rank Fund Capital Flow
1
BG
Bellevue Group
Switzerland
+$24.4M
2
Millennium Management
Millennium Management
New York
+$9.4M
3
YCM
Yiheng Capital Management
California
+$6.55M
4
Two Sigma Investments
Two Sigma Investments
New York
+$4.24M
5
Renaissance Technologies
Renaissance Technologies
New York
+$4M

Top Sellers

Rank Fund Capital Flow
1
CG
Carmignac Gestion
France
-$36.9M
2
JP Morgan Chase
JP Morgan Chase
New York
-$21.8M
3
Victory Capital Management
Victory Capital Management
Texas
-$20.5M
4
Ensign Peak Advisors
Ensign Peak Advisors
Utah
-$10.8M
5
Goldman Sachs
Goldman Sachs
New York
-$4.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$61.2M +$330K +1,890 +0.2%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$60.4M +$338K +1,937 +0.2%
AVLSA
3
Atlas Venture Life Science Advisors
Massachusetts
$58.6M +$145M +827,888 New
BG
4
Bellevue Group
Switzerland
$27.4M +$24.4M +140,000 +57%
Vanguard Group
5
Vanguard Group
Pennsylvania
$25.4M +$757K +4,338 +1%
FCM
6
Farallon Capital Management
California
$24.8M – – –
BlackRock
7
BlackRock
New York
$22.4M +$742K +4,252 +1%
AG
8
Artal Group
Luxembourg
$19.9M – – –
YCM
9
Yiheng Capital Management
California
$14M +$6.55M +37,538 +23%
State Street
10
State Street
Massachusetts
$13.8M +$2.36M +13,536 +7%
CC
11
Casdin Capital
New York
$9.38M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$5.3M -$653K -3,742 -5%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$4.31M -$586K -3,356 -5%
JP Morgan Chase
14
JP Morgan Chase
New York
$3.98M -$21.8M -124,797 -69%
Millennium Management
15
Millennium Management
New York
$3.81M +$9.4M +53,839 New
HMC
16
Harvard Management Company
Massachusetts
$3.61M – – –
Northern Trust
17
Northern Trust
Illinois
$2.98M -$268K -1,534 -4%
Charles Schwab
18
Charles Schwab
California
$2.26M +$239K +1,367 +4%
N
19
Nuveen
North Carolina
$1.86M -$188K -1,075 -7%
Morgan Stanley
20
Morgan Stanley
New York
$1.73M +$128K +735 +3%
Two Sigma Investments
21
Two Sigma Investments
New York
$1.72M +$4.24M +24,298 New
TD Asset Management
22
TD Asset Management
Ontario, Canada
$1.68M +$843K +4,828 +25%
Renaissance Technologies
23
Renaissance Technologies
New York
$1.62M +$4M +22,890 New
BI
24
BVF Inc
California
$1.34M +$3.3M +18,905 New
Bank of America
25
Bank of America
North Carolina
$1.19M +$2.37M +13,556 +415%
1
2 3 4 5

GBIO Hedge Fund Activity: Q4 2021 in Review

88 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q4 2021, worth a combined $390M — down 68% from $1.2B a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new GBIO positions and 14 closed out — a net gain of 8 holders — while 29 added to existing stakes and 23 trimmed.

The largest buyer was Bellevue Group, adding an estimated $24.4M. The largest seller was Carmignac Gestion, exiting entirely with an estimated $36.9M sold.

  • 88 institutional investors held Generation Bio (GBIO) as of Q4 2021, up from 81 in Q3 2021.
  • Funds reported $390M of Generation Bio stock for Q4 2021, down 68% quarter-over-quarter.
  • 22 funds opened new Generation Bio positions in Q4 2021 and 14 closed out, a net change of +8 holders.
  • The largest Generation Bio buyer in Q4 2021 was Bellevue Group, an estimated $24.4M added.
  • The largest Generation Bio seller in Q4 2021 was Carmignac Gestion, an estimated $36.9M sold.

Based on aggregated 13F filings for Q4 2021.